Peripheral Nerve Allograft Hydrogel for Localized Immunosuppression

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for peripheral nerve repair, such as conduits and processed allografts, fail to match the regeneration associated with sensory autografts, and autografts suffer from size mismatch, neuroma formation, and immunosuppression risks, while allografts face systemic immunosuppression complications.

Innovation Solution

Localized immunosuppression using hydrogel carriers with polymeric nanoparticles delivering immunosuppressive agents, Tregs, and antibodies to peripheral nerve allografts, minimizing systemic side effects and enhancing nerve regeneration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If processed allografts are used for peripheral nerve repair, then nerve regeneration is achieved, but regeneration quality does not match sensory autografts

Engineering Contradiction:

Improvenerve regeneration qualityVSAvoidregeneration efficiency

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent applies local quality by creating a localized immunosuppressive environment around the allograft nerve using hydrogel carriers containing immunosuppressive agents. This localized treatment enhances regeneration quality at the graft site without affecting the entire organism, allowing processed allografts to achieve regeneration quality comparable to sensory autografts while maintaining the benefits of allograft availability.

Inventive Principle:

Principle #3Local quality

2Reliability

If systemic immunosuppression is used to prevent allograft rejection, then graft acceptance is improved, but patient morbidity increases due to infections and renal damage

Engineering Contradiction:

Improvegraft acceptanceVSAvoidopportunistic infections and renal damage

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent implements local quality by delivering immunosuppressive agents locally to the allograft site through hydrogel carriers rather than systemically. This localized delivery suppresses rejection at the graft interface while minimizing systemic exposure, thereby maintaining graft acceptance while reducing harmful effects such as opportunistic infections and renal damage associated with systemic immunosuppression.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The hydrogel carrier acts as an intermediary between the immunosuppressive agents and the allograft tissue. The hydrogel delivers the immunosuppressive agents directly to the graft site, mediating the interaction between the drug and target tissue while controlling local concentration and duration of action, thus achieving effective graft acceptance with minimal systemic side effects.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Reliability

If continuous systemic immunosuppression is maintained, then chronic rejection is prevented, but patient compliance deteriorates

Engineering Contradiction:

Improveprotection against chronic rejectionVSAvoidpatient compliance

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent applies preliminary action by incorporating immunosuppressive agents into hydrogel carriers that are placed at the allograft site during surgery. These agents are released locally over time, providing preemptive protection against chronic rejection without requiring ongoing patient participation. This eliminates the need for continuous patient compliance with systemic immunosuppressive medication regimens.

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The localized hydrogel delivery system provides self-service immunosuppression at the graft site. The hydrogel carriers autonomously release immunosuppressive agents locally, protecting the allograft from chronic rejection without requiring external patient intervention or compliance with medication schedules, thereby solving the compliance problem while maintaining protection against chronic rejection.

Inventive Principle:

Principle #25Self-service

4Device complexity

If allografts are used instead of autografts, then surgical complexity is reduced, but immune response against the graft increases

Engineering Contradiction:

Improvesurgical procedure complexityVSAvoidimmune response and rejection

Core Design Contradiction:

Device complexityVSObject-generated harmful factors

Solution Approach 1:

The patent applies local quality by creating a localized immunosuppressive microenvironment around the allograft using hydrogel carriers. This localized approach maintains the surgical simplicity of allograft implantation while counteracting the increased immune response through targeted local immunosuppression, allowing the use of allografts without requiring complex surgical procedures or accepting high rejection rates.

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS12599561B2Localized immunosuppression of allografts for peripheral nerve repair

Publication Date: 2026.04.14 UNIVERSITY OF WYOMING

AI summary

Embodiments described herein relate to restorative solutions for segmental peripheral nerve (PN) defects using allografted PNs for stimulating PN repair. More specifically, embodiments described herein provide for localized immunosuppression (LIS) surrounding PN allografts as an alternative to systemically suppressing a patient's entire immune system. Methods include localized release of immunosuppressive (ISV) agents are contemplated in one embodiment. Methods also include localized application of immunosuppressive (ISV) regulatory T-cells (Tregs) and/or mesenchymal stomal cells in other embodiments. Hydrogel carrier materials are also described herein.